Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, FVT

Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018

SAN DIEGO, March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018, after the market close.  Pfenex management will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the financial results and provide a business update.

Pfenex logo (PRNewsFoto/Pfenex)

Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call.  A replay of the conference call will be available approximately one hour after the call until March 22, 2018.  To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10117964.  The conference call will also be available as a webcast.  To access the webcast link please log on to www.pfenex.com (http://www.pfenex.com).

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com), our investor relations website (http://pfenex.investorroom.com), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.  We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information.  Please note that this list may be updated from time to time.

About Pfenex Inc.

Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.


SOURCE Pfenex Inc.

These press releases may also interest you

at 08:00
Scality, leader in software solutions for distributed file and object storage and multi-cloud data control, today announced the availability of Zenko 1.0, the industry's first and only cloud-native multi-cloud data controller.  Available now in both...

at 08:00
Viasat Inc. , a global communications company, today announced it signed Intelisys, Inc., a ScanSource company and the nation's leading Technology Services Distributor, as its latest Master Agent partner offering Viasat's business internet services....

at 08:00
BNY Mellon has announced its appointment as Depositary, Trustee, Registrar, Transfer Agent, Paying Agent, and Settlement Agent for the conversion of US$20 billion of defaulted debt into new bonds and equities via American Depositary Receipts and...

at 08:00
Most folks don't realize the convenience of their natural gas and electric service until it's not there. Fortunately, customers of Louisville Gas and Electric Company and Kentucky Utilities Company have continued to experience safer, more reliable...

at 08:00
FREDERICK, Md., Sept. 19, 2018 /PRNewswire-PRWeb/ -- For a tightly niched audience, "The Zesty Marketing Podcast" delivers an edu-tational way to eavesdrop on conversations with marketing professionals from destinations and attractions. In its first...

at 08:00
Oracle Retail has introduced a new Oracle Retail Assortment and Item Planning Cloud Service for fashion and softline retailers. Delivering an effective assortment and item strategy that engages the customer in an omnichannel environment requires a...

News published on 8 march 2018 at 16:15 and distributed by: